Blog
RSS FeedPosted by Michael Wonder on 09 Aug 2024
Enzalutamide for the treatment of patients with non-metastatic prostate cancer after radical prostatectomy or radiotherapy
8 August 2024 - NICE is unable to make a recommendation about the use in the NHS of enzalutamide for the ...
Posted by Michael Wonder on 08 Aug 2024
World’s first gene editing therapy for blood disorder to be available to hundreds of patients in England
8 August 2024 - Patients in England with severe beta-thalassaemia will be amongst the first in Europe to benefit from one-time ...
Posted by Michael Wonder on 08 Aug 2024
Vertex announces Casgevy reimbursement agreement for the treatment of transfusion-dependent beta thalassemia in England
7 August 2024 - Eligible transfusion-dependent beta thalassaemia patients in England will be able to access the therapy from today. ...
Posted by Michael Wonder on 07 Aug 2024
14,000 women at risk of fractures after the menopause to benefit from bone disease drug
8 August 2024 - Over 14,000 people to benefit after NICE published final guidance recommending abaloparatide as an option for treating ...
Posted by Michael Wonder on 07 Aug 2024
Durvalumab in combination with chemotherapy before surgery (neo-adjuvant) then alone after surgery (adjuvant) for the treatment of adults with resectable non-small-cell lung cancer
30 July 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 07 Aug 2024
Burosumab for the treatment of adults with X-linked hypophosphataemia
7 August 2024 - NICE has issued evidence-based recommendations on the use burosumab (Crysvita) for the treatment of adults X‑linked ...
Posted by Michael Wonder on 07 Aug 2024
Abaloparatide for the treatment of women with osteoporosis after menopause
6 August 2024 - NICE has issued dvidence-based recommendations on the use of abaloparatide (Eladynos) for treatment of osteoporosis after ...
Posted by Michael Wonder on 06 Aug 2024
Maralixibat chloride for the treatment of patients with cholestatic pruritus associated with Alagille syndrome
31 July 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 01 Aug 2024
Introducing a new way of prioritising our guidance topics
30 July 2024 - NICE's deputy chief executive, Jonathan Benger, talks about our new approach to prioritisation. ...
Posted by Michael Wonder on 01 Aug 2024
First targeted treatment made available for hundreds of blood cancer patients on the NHS
1 August 2024 - A take at home tablet which could be a ‘game-changer’ for hundreds of blood cancer patients ...
Posted by Michael Wonder on 30 Jul 2024
NICE disappointed companies unwilling to offer fair price to make Enhertu available for advanced breast cancer
29 July 2024 - Daiichi Sankyo and partner company AstraZeneca have been unwilling to offer a price that would enable NICE ...
Posted by Michael Wonder on 25 Jul 2024
New clot busting drug recommended by NICE set to save NHS millions of pounds
24 July 2024 - Giving a new clot busting drug to people who have had a stroke could help save the ...
Posted by Michael Wonder on 19 Jul 2024
More than 40,000 people could benefit after NICE recommends new ‘take at home’ pill for advanced prostate cancer
19 July 2024 - A new pill to treat advanced hormone sensitive prostate cancer that could benefit just over 40,000 ...
Posted by Michael Wonder on 18 Jul 2024
Rucaparib camsylate for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy
8 July 2024 - The Department of Health and Social Care has asked the NICE to produce guidance on the ...
Posted by Michael Wonder on 16 Jul 2024
Elranatamab for the treatment of patients with relapsed and refractory multiple myeloma after three or more treatments
12 July 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...